PTGER3 and cardiovascular disorder: Although EP3 antagonists are not widely used in clinical therapy, research has demonstrated that blockade of EP3 has been linked to numerous therapeutic areas, including the treatment of pain, diabetes, and cardiovascular disease, specifically thrombosis [48, 49].